Loading data for CANF — first visit, this takes a few seconds.

Alerta

Can-Fite BioPharma Ltd. (CANF)

NYSE American: CANF · Precio en tiempo real · USD

3.45

-0.13 (-3.63%)

Al cierre: Aug 18, 2026, 3:52 PM

3.59

+6.68%

Premercado: 8:02 AM

-3.63% (1D)

Precio de compra	n/a
Capitalización de mercado	7.39M
Ingresos (TTM)	405K
Beneficio neto (TTM)	-9.83M
Beta	-0.04
EPS (TTM)	-10.75
Ratio PER (TTM)	n/a
Adelante PE	-12.78
P/B (TTM)	0.81
P/S (TTM)	18.25
Earnings Date	Mar 27, 2020

Precio de venta	n/a
Volumen	29,446
Volumen medio (20D)	1,436,753
Abierto	3.54
Anterior Cerrar	3.58
Rango del día	3.37 - 3.56
Rango de 52 semanas	2.56 - 13.60
analista	n/a
Precio objetivo	n/a
Dividendos	n/a
Fecha ex dividendo	n/a

Acerca de CANF

Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops orally bioavailable small molecule therapeutic products for the treatment of cancer, liver inflammatory diseases, and erectile dysfunction in Israel. The company's lead drug candidate Piclidenoson, which has been completed Phase III clinical trial for the treatment of psoriasis. It develops Namodenoson that is in Phase III clinical trial for the treatment of liver cance...

[Leer más]

Industria Biotechnology

Sector Healthcare

IPO Fecha Nov 6, 2012

Empleados 5

Bolsa de Valores NYSE American

Símbolo bursátil CANF

Sitio web https://www.canfite.com

Perfil completo de la empresa

Desempeño financiero

En 2025, los ingresos de Can-Fite BioPharma fueron 405K, una disminución de -39.91% en comparación con 674K del año anterior. Las ganancias fueron -9.83M, un aumento de 24.72%.

Estados financieros

Sorpresa de resultados

Can-Fite BioPharma ha publicado sus resultados trimestrales en Mar 28, 2024:

Ingresos de n/a falla las estimaciones por $0, con NaN% Crecimiento interanual.

EPS de -60 falla las estimaciones por -52.60, con 0.00% Crecimiento interanual.

Próxima publicación de resultados

Está previsto que Can-Fite BioPharma Ltd. publique sus resultados el Mar 27, 2020, antes de que se abra el mercado.
Los analistas proyectan ingresos de ... Actualizar

Noticias

1 mes hace · MT Newswires

Sector Update: Healthcare Stocks Higher Late Afternoon

Healthcare stocks were higher late Wednesday afternoon, with the NYSE Healthcare Index up 0.1% and t

5 meses hace · Zacks

CANF Stock Soars 20% on Positive Mid-Stage Pancreatic Cancer Data

Can-Fite stock jumps 20% after mid-stage data show namodenoson is well tolerated in advanced pancreatic cancer patients, meeting the study's primary safety endpoint.

7 meses hace · MT Newswires

Sector Update: Health Care Stocks Edge Higher Late Afternoon

Health care stocks were edging up late Friday afternoon with the NYSE Health Care Index and the Stat

7 meses hace · MT Newswires

Sector Update: Health Care Stocks Lower in Friday Afternoon Trading

Health care stocks declined Friday afternoon, with the NYSE Health Care Index and the State Street H

7 meses hace · MT Newswires

Top Midday Stories: Nvidia-Groq Licensing Deal; Target Attracts Growing Interest From Toms Capital

All three major US stock indexes were edging lower in midday trading on Friday following the Christm

Página 1 de 2

Can-Fite BioPharma Ltd. (CANF)